Last reviewed · How we verify
Corpus Luteum Insufficiency Syndrome — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Endometrin | progesterone | Ferring | Progesterone [EPC] | Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1 | ||
| Progesteron | Progesteron | Minia University | Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Ferring · 1 drug in Corpus Luteum Insufficiency Syndrome
- Minia University · 1 drug in Corpus Luteum Insufficiency Syndrome
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Corpus Luteum Insufficiency Syndrome:
- Corpus Luteum Insufficiency Syndrome treatment updates — RSS
- Corpus Luteum Insufficiency Syndrome treatment updates — Atom
- Corpus Luteum Insufficiency Syndrome treatment updates — JSON
Cite this brief
Drug Landscape (2026). Corpus Luteum Insufficiency Syndrome — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/corpus-luteum-insufficiency-syndrome. Accessed 2026-06-10.
Related
- Corpus Luteum Insufficiency Syndrome full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing